Ultimovacs ASA (STU:7UM) Accounts Payable & Accrued Expense : €1.40 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Accounts Payable & Accrued Expense?

Ultimovacs ASA's quarterly accounts payable & accrued expense increased from Sep. 2023 (€2.06 Mil) to Dec. 2023 (€3.62 Mil) but then declined from Dec. 2023 (€3.62 Mil) to Mar. 2024 (€1.40 Mil).

Ultimovacs ASA's annual accounts payable & accrued expense declined from Dec. 2021 (€4.16 Mil) to Dec. 2022 (€2.88 Mil) but then increased from Dec. 2022 (€2.88 Mil) to Dec. 2023 (€3.62 Mil).

Ultimovacs ASA Accounts Payable & Accrued Expense Historical Data

The historical data trend for Ultimovacs ASA's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Accounts Payable & Accrued Expense Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.65

1.76

4.16

2.88

3.62

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.79	2.16	2.06	3.62	1.40

Ultimovacs ASA Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Ultimovacs ASA (STU:7UM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines